Purpose of Review: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a phenotypic designation of the broader condition of chronic rhinosinusitis. The advent of targeted biologics has shown promise in targeting different aspects of the inflammatory pathway, yet there remains a lack of consensus on the correct timing and use of these medications. This review seeks to provide a concise update of the available literature on the pathophysiology of CRSwNP, the evolution and cost utility of biologics as it pertains to management of patients with CRSwNP, and evidence for each available biologic and its use in CRSwNP.
Recent Findings: There are two biologics with FDA approval for use in CRSwNP: dupilumab and omalizumab. Recent clinical trials of other biologic therapies targeting type 2 inflammatory pathways have also demonstrated efficacy both in symptom scores and nasal polyp reduction. However, studies have questioned the cost utility of these medications compared to other interventions. Furthermore, timing of use with respect to other interventions including surgery remains challenging.

Keywords: chronic rhinosinusitis with nasal polyposis, biologics, nasal polyps, management of nasal polyps


中文翻译：

---

生物制剂时代慢性鼻窦炎伴鼻息肉的治疗

审查目的：慢性鼻窦炎伴鼻息肉病 (CRSwNP) 是慢性鼻窦炎更广泛疾病的表型名称。靶向生物制剂的出现已显示出靶向炎症通路不同方面的前景，但对于这些药物的正确时机和使用仍缺乏共识。本综述旨在提供有关 CRSwNP 病理生理学、生物制剂在 CRSwNP 患者管理方面的演变和成本效用的现有文献的简明更新，以及每种可用生物制剂及其在 CRSwNP 中的应用的证据。
最近的发现：有两种生物制剂获得 FDA 批准用于 CRSwNP：dupilumab 和 omalizumab。最近针对 2 型炎症通路的其他生物疗法的临床试验也证明了在症状评分和鼻息肉减少方面的有效性。然而，与其他干预措施相比，研究质疑这些药物的成本效用。此外，包括手术在内的其他干预措施的使用时机仍然具有挑战性。

关键词：慢性鼻窦炎伴鼻息肉，生物制剂，鼻息肉，鼻息肉治疗